Estimaciones de analistas de Wall Street para Precision BioSciences, Inc. (DTIL): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 9 |
| Mantener | 3 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 12 |
| Calificación media (1-5) | 0.75 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-02 | $-0.85 | ||
| 2026-08-06 | $-1.26 | $-0.80 | -56.7% |
| 2026-05-05 | $-0.75 | $-0.27 | -177.8% |
| 2026-03-12 | $1.05 | $-0.21 | +600.0% |
| 2025-11-03 | $-1.84 | $-0.31 | -493.5% |
| 2025-08-07 | $-2.13 | $-0.09 | -2266.7% |
| 2025-05-15 | $-2.21 | $-0.43 | -414.0% |
| 2025-03-26 | $-3.20 | $-2.09 | -53.1% |
Ratios de valoración
| Precio / Valor contable | 3.78 |
| EV / EBITDA | -0.76 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $7.0M | $6.5M | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | $7.0M | $6.5M | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| I+D | $9.1M | $20.3M | $45.1M | $82.4M | $98.1M | $115.2M | $46.1M | $53.4M | $59.6M | $54.2M |
| Generales y Administrativos | $6.1M | $8.0M | $13.7M | $27.0M | $36.1M | $39.7M | $41.3M | $39.1M | $35.3M | $32.2M |
| Gastos Operativos | $15.2M | $28.3M | $58.8M | $109.4M | $134.1M | $154.9M | $87.4M | $92.5M | $94.9M | $86.4M |
| Beneficio Operativo | -$8.8M | -$22.0M | -$47.9M | -$87.2M | -$109.8M | -$39.4M | -$62.3M | -$43.7M | -$26.2M | -$52.1M |
| EBITDA | -$8.2M | -$20.4M | -$43.7M | -$87.4M | -$99.2M | -$20.3M | -$62.8M | -$32.0M | $13.5M | -$42.4M |
| Gastos por Intereses | 0 | 0 | 0 | $182000 | 0 | $132000 | $1.1M | $2.2M | $1.8M | $1.4M |
| Beneficio Antes de Impuestos | -$8.3M | -$21.1M | -$46.0M | -$92.9M | -$109.0M | -$30.6M | -$72.9M | -$42.5M | $7.2M | -$46.6M |
| Impuestos | -$5000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$8.3M | -$21.1M | -$46.0M | -$92.9M | -$109.0M | -$30.6M | -$111.6M | -$61.3M | $7.2M | -$45.7M |
| BPA | $-0.49 | $-18.81 | $-28.17 | $-59.50 | $-62.85 | $-15.60 | $-38.10 | $-15.96 | $1.05 | $-3.56 |
| BPA Diluido | $-0.49 | $-18.81 | $-28.17 | $-59.50 | $-62.85 | $-15.60 | $-38.10 | $-15.96 | $1.04 | $-3.56 |
| Acciones en Circulación (Diluidas) | $16.7M | $1.1M | $1.6M | $1.4M | $1.7M | $2.0M | $2.9M | $3.8M | $6.9M | $12.8M |
Precio
| Precio | $6.63 |
| Capitalización | $85M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ABOS · ALEC · GOSS · HOOK · HRTX · KLDO · QTTB
Explorar sector: Healthcare · Biotechnology
Más secciones de DTIL: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones